Acasti Pharma Inc. Reports Positive Impacts on Obesity and Cardiometabolic Associated Disorders
2010年9月2日 - 8:30PM
Acasti Pharma Inc., a subsidiary of Neptune Technologies &
Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX-V:NTB) reports
significant results on the effects of its anti-dyslipidemic
investigational drug candidate CaPre™ on C-reactive protein (CRP)
levels, a biomarker of CardioVascular Disease risk (CVD) and
associated with diabetes and obesity.
The study demonstrated that severe dyslipidemic and metabolic
syndrome (pre-diabetic) subjects, treated once-daily with either
0.5g or 2.5g CaPre™ human equivalent dosing per day for 28 days,
benefited from the treatment resulting in a reduction of CRP levels
by 15% and 24%, respectively. It is recognized by the American
Heart Association that testing CRP levels in the blood may be an
additional way to assess cardiovascular disease risk. In
addition, the prevalence of high CRP levels is accentuated in
overweight and obese individuals now affecting 60% of the
population of 20 years and over according to the Centers for
Disease Control and Prevention (Atlanta, USA).
"The present results clearly suggest a beneficial lowering
effect of CaPre™ on CRP. This observation, combined with our
previous findings that CaPre™ reduces triglycerides and
LDL-cholesterol (bad cholesterol) and elevates HDL-cholesterol
(good cholesterol), indicates that CaPre™ offers a more complete
protection against severe dyslipidemia and associated systemic
inflammatory conditions as cardiometabolic syndrome," said
Dr. Farhad Amiri, Associate-Director, Preclinical Studies,
R&D.
"Accumulating evidence in the literature indicates that
C-reactive protein, may be as important as LDL-cholesterol in
assessing the development of atherosclerosis ("hardening of the
arteries") and heart disease," said Dr. Pierre Lemieux, Chief
Operating Officer of Acasti. "Chronic inflammation is
associated with the most prevalent health problems today such as
obesity and diabetes. Similar to the JUPITER trial showing a
CVD benefit of statin lowering CRP, a reduction in CRP by CaPre™,
may constitute an additional tool in the systemic management of
800,000 myocardial infractions and 700,000 strokes that occur in
the United States each year," he added.
About Neptune
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing
consumer health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The
Company sponsors clinical trials aimed to demonstrate its product
health benefits and to obtain regulatory approval for label health
claims. Neptune is continuously expanding its intellectual
property portfolio as well as clinical studies and regulatory
approvals. Neptune's products are marketed and distributed in
over 20 countries worldwide.
About Acasti Pharma Inc.
Acasti Pharma is developing a product portfolio of proprietary
novel long-chain omega-3 phospholipids. Phospholipids are the
major component of cell membranes and are essential for all vital
cell processes. They are one of the principal constituents of
High Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti
Pharma's proprietary novel phospholipids carry and functionalize
the polyunsaturated omega-3 fatty acids EPA and DHA, which have
been shown to have substantial health benefits and which are
stabilized by potent antioxidants. Acasti Pharma is focusing
initially on treatments for chronic cardiovascular conditions
within the over-the-counter, medical food and prescription drug
markets.
About NeuroBioPharm
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development
of a prescription drug candidate is currently in progress.
Advanced clinical development and commercialization is planned to
be carried out with multinational partners.
"Neither NASDAQ nor the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release."
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking statements"
within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and Canadian securities laws. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the
actual results of the Company to be materially different from
historical results or from any future results expressed or
implied by such forward-looking statements. In addition
to statements which explicitly describe such risks and
uncertainties, readers are urged to consider statements labeled
with the terms "believes," "belief," "expects," "intends,"
"anticipates," "will," or "plans" to be uncertain and
forward-looking. The forward-looking statements contained herein
are also subject generally to other risks and uncertainties that
are described from time to time in the Company's reports filed with
the Securities and Exchange Commission and the Canadian
securities commissions.
CONTACT: Neptune Technologies & Bioressources Inc.
Andre Godin, Vice President, Finance & Administration
450-687-2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
Acasti Pharma Inc.
Tina Sampalis, President
450-686-4555 (ext : 403)
t.sampalis@acastipharma.com
www.acastipharma.com
Howard Group
Grant Howard
(888) 221-0915
grant@howardgroupinc.com
www.howardgroupinc.com
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 6 2024 まで 7 2024
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 7 2023 まで 7 2024